Clarity Peptide Imaging services

Clarity’s Mission

 

At Clarity, our mission is to develop innovative radiopharmaceutical products and offer seamless preclinical to clinical imaging services that ensure better patient outcomes.

 

Clarity is a personalised medicine company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceutical technology, developing targeted therapies and assisting in the drug development pipeline of novel therapies for companies globally. It was established in 2010 as a private, Sydney-based life sciences company.

Clarity’s platform technology allows antibodies to be radiolabeled and visualised using PET imaging. The human imaging data generated provides information on whether the drug reaches the desired disease target in a patient. This information enables a personalised approach to therapy by only treating those patients that are likely to respond to therapy and excluding those that won’t respond to therapy. This precision medicine approach is at the forefront of drug development.

Find out more
pharmaceutical development

Pharmaceutical Development

 

Clarity adds value to antibodies and peptides by creating personalised medicine imaging drugs. By using its proprietary imaging technology, Clarity develops companion imaging diagnostics to therapeutic antibodies and peptides.

 

Clarity Pharmaceuticals also actively manages an in-house drug development program, with its first drug (an oncology companion diagnostic) about to enter clinical trials. Clarity plans to expand its program to include further development of antibodies and peptides whose clinical trials might benefit from patient selection using the company’s imaging technology.
Clarity Pharmaceuticals is currently based in Sydney, Australia, and is successfully leveraging the country’s attractive R&D tax rebates, an advantageous regulatory framework and world class infrastructure facilities.

Find out more
imaging services

Antibody and Peptide Imaging Services

 

Clarity Pharmaceuticals offers it’s imaging services to groups with antibodies and peptides in development.

 

Imaging biopharmaceuticals in early stage development allows developers to visualise where their antibody or peptide is going, including targeting, off-target binding, clearance and biodistribution. This de-risks the development process, and allows companies to make early decisions about their antibody and peptide drug candidates.

antibody imaging service
peptide imaging service
imaging services
Find out more
Clarity Peptide Imaging services

News

 

Find out the latest news about Clarity Pharmaceuticals

news-wallonia

Clarity awarded EUR950,000 Belgium government grant to develop vulnerable plaque diagnostic

Sydney, Australia 11 August 2016 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, including cancer and heart disease, has been awarded a Belgium government grant of approximately EUR950,000 under the Wallonia region COOTECH program. The grant is funded by the European Union and the Directorate General for Economy, Employment…

Details

news-crc-grant

Clarity awarded $2.5 million CRC-Projects Grant

Sydney, Australia 27 June 2016 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious diseases, especially cancer, has been awarded a Cooperative Research Centres Projects (CRC-P) grant. This grant is part of the Australian Government’s Cooperative Research Centres Programme. The grant, valued at $2,513,000, will fund the extension of Clarity’s capabilities of…

Details

news-ansto

ANSTO provides groundwork for promising new nuclear medicine

Building on comprehensive work of a former ANSTO researcher Prof Suzanne Smith, Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has progressed its lead product SARTATE™ from the lab into the clinic for treatment of a range of cancers including neuroendocrine tumours and childhood cancers. The product, a promising molecular imaging…

Details
Find out more